Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events

Expert Review of Cardiovascular Therapy

Volumn 14, Issue 7, 2016, Pages 779-791

  Bliden, Kevin P ^a   Tantry, Udaya S ^a   Chaudhary, Rahul ^a   Byun, Seunghwan ^a   Gurbel, Paul A ^a  

^a INOVA HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

acetylsalicylic acid; Antiplatelet; aspirin; cardiovascular disease; platelet; secondary prevention; thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG RELEASE; DRUG USE; EXTENDED DRUG RELEASE; HUMAN; MEDLINE; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; SINGLE DRUG DOSE; STANDARD; CARDIOVASCULAR DISEASES; STROKE;

ANTICOAGULANTS; ASPIRIN; CARDIOVASCULAR DISEASES; HUMANS; PLATELET AGGREGATION INHIBITORS; SECONDARY PREVENTION; STROKE;

EID: 84973160858     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1080/14779072.2016.1188005     Document Type: Article

References (78)

1. D.Mozaffarian, E.J.Benjamin, A.S.Go, et al. Heart disease and stroke statistics-2015 update: a report from the american heart association. Circulation. 2015;131:e29–e322.
2. P.A.Gurbel, K.P.Bliden, K.M.Hayes, et al. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther. 2004;2:535–545.
3. H.N.Bradford, S.Krishnaswamy The fragment 1 region of prothrombin facilitates the favored binding of fragment 12 to zymogen and enforces zymogen-like character in the proteinase. J Biol Chem. 2016 March 24. [Epub ahead of print].
4. P.A.Gurbel, U.S.Tantry Combination antithrombotic therapies. Circulation. 2010;121:569–583.
5. U.S.Tantry, K.P.Bliden, P.A.Gurbel. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005;46:1705–1709.● Describes various types of platelet function testing commonly used.
6. A.S.Khan, S.Chaudhry, A.I.Qureshi. Antithrombotic utilization trends after noncardioembolic ischemic stroke or TIA in the setting of large antithrombotic trials (2002–2009). J Vasc Interv Neurol. 2015;8:20–26.
7. S.D.Wiviott, P.G.Steg. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet. 2015;386:292–302.
8. S.C.SmithJr, E.J.Benjamin, R.O.Bonow, et al. The world heart federation and the preventive cardiovascular nurses association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American heart association and American College of Cardiology Foundation. Circulation. 2011;124:2458–2473.
9. American Diabetes Association. Position statement section 8: cardiovascular disease and risk management. Diabetes Care. 2015;38:S49–S57.
10. B.M.Scirica, M.P.Bonaca, E.Braunwald, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial. Lancet. 2012;380:1317–1324.
11. L.Wallentin, R.C.Becker, A.Budaj, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
12. S.D.Wiviott, E.Braunwald, C.H.McCabe, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015.
13. K.P.Bliden, J.Patrick, A.T.Pennell, et al. Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. Future Cardiol. 2016;12:45–58.● Ref reviews current knowledge of extended release aspirin.
14. U.S.Tantry, E.Mahla, P.A.Gurbel. Aspirin resistance. Prog Cardiovasc Dis. 2009;52:141–152.
15. Durlaza (aspirin) extended release capsules, for oral use [package insert]. North Haven, CT: New Haven Pharmaceuticals; 2015.
16. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;332:349–360.
17. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339.
18. H.C.Diener, L.Cunha, C.Forbes, et al. European stroke prevention study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1–13.
19. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet. 1997;349:1569–1581.
20. CAST Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349:1641–1649.
21. S.Yusuf, F.Zhao, S.R.Mehta, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.
22. R.J.Peters, S.R.Mehta, K.A.Fox, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682–1687.
23. S.R.Steinhubl, P.B.Berger, J.T.MannIII, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–2420.
24. H.C.Diener, J.Bogousslavsky, L.M.Brass, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331–337.
25. Z.M.Chen, L.X.Jiang, Y.P.Chen, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607–1621.
26. D.L.Bhatt, K.A.Fox, W.Hacke, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–1717.
27. D.L.Bhatt, M.D.Flather, W.Hacke, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982–1988.
28. S.R.Mehta, J.F.Tanguay, J.W.Eikelboom, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233–1243.
29. Y.Wang, Y.Wang, X.Zhao, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11–19.
30. C.Baigent, L.Blackwell, R.Collins, et al. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860.
31. C.Baigent, R.Collins, P.Appleby, et al. ISIS-2: 10-year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) collaborative group. BMJ. 1998;316:1337–1343.
32. K.L.Furie, S.E.Kasner, R.J.Adams, et al. American Heart Association Stroke Council, council on cardiovascular nursing, council on clinical cardiology, and interdisciplinary council on quality of care and outcomes research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:227–276.
33. E.A.Amsterdam, N.K.Wenger, R.G.Brindis, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:e344–e426.
34. M.Roffi, C.Patrono, J.P.Collet, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267–315.
35. S.Windecker, P.Kolh, F.Alfonso, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–2619.
36. P.T.O’Gara, F.G.Kushner, D.D.Ascheim, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:e78–140.
37. P.G.Steg, S.K.James, D.Atar, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–2619.
38. G.N.Levine, E.R.Bates, J.C.Blankenship, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation. 2011;124:e574–e651.
39. G.Montalescot, U.Sechtem, S.Achenbach, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949–3003.
40. C.Patrono, G.Ciabattoni, P.Patrignani, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72:1177–1184.
41. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Bmj. 2002;324:71–86.
42. S.R.Steinhubl, D.L.Bhatt, D.M.Brennan, et al. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med. 2009;150:379–386.
43. J.S.Berger, R.H.Sallum, B.Katona, et al. Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. Am Heart J. 2012;164:153–162.
44. C.L.Campbell, S.Smyth, G.Montalescot, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. Jama. 2007;297:2018–2024.
45. J.R.Vane, R.M.Botting. The mechanism of action of aspirin. Thromb Res. 2003;110:255–258.
46. M.M.Wolfe, D.R.Lichtenstein, G.Singh. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888–1899.
47. M.J.Antonino, R.Coppolecchia, E.Mahla, et al. Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. Thromb Res. 2010;126:384–385.
48. N.Faraday, D.M.Becker, L.R.Yanek, et al. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol. 2006;98:774–779.
49. M.Lordkipanidze, C.Pharand, E.Schampaert, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007;28:1702–1708.
50. C.Patrono, C.Baigent, J.Hirsh, et al. Antiplatelet drugs: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:199S–233S.
51. C.Patrono, B.Rocca. Drug insight: aspirin resistance–fact or fashion? Nat Clin Pract Cardiovasc Med. 2007;4:42–50.
52. P.A.Gurbel, K.P.Bliden, J.DiChiara, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007;115:3156–3164.●● Ref describes the effect of aspirin dosing on platelet function.
53. J.DiChiara, K.P.Bliden, U.S.Tantry, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the Aspirin-Induced Platelet Effect (ASPECT) study. Diabetes. 2007;56:3014–3019.●● Ref describes aspirin response in patients with Type II diabetes.
54. B.Rocca, P.Secchiero, G.Ciabattoni, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A. 2002;99:7634–7639.
55. N.Zimmermann, A.Wenk, U.Kim, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation. 2003;108:542–547.
56. J.W.Eikelboom, G.J.Hankey, J.Thom, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation. 2008;118:1705–1712.
57. J.W.Eikelboom, J.Hirsh, J.I.Weitz, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–1655.
58. P.Henry, A.Vermillet, B.Boval, et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost. 2011;105:336–344.
59. C.Perneby, N.H.Wallen, C.Rooney, et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost. 2006;95:652–658.
60. M.Lordkipanidze, C.Pharand, E.Schampaert, et al. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. Int J Cardiol. 2011;150:39–44.
61. M.Würtz, A.M.Hvas, L.O.Jensen, et al. 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. Int J Cardiol. 2014;175:274–279.
62. B.Rocca, F.Santilli, D.Pitocco, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost. 2012;10:1220–1230.
63. K.H.Christensen, E.L.Grove, M.Wurtz, et al. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. Platelets. 2015;26:230–235.
64. T.N.Bonten, A.Saris, M.J.Van Oostrom, et al. Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial. Thromb Haemost. 2014;112:1209–1218.
65. D.Capodanno, A.Patel, K.Dharmashankar, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv. 2011;4:180–187.
66. J.G.Dillinger, A.Drissa, G.Sideris, et al. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. Am Heart J. 2012;164:600–606.● Ref Describes the response of twice daily ASA dosing in patients with CAD.
67. G.Spectre, L.Arnetz, C.G.Östenson, et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost. 2011;106:491–499.
68. T.Hoefer, P.C.Armstrong, M.Finsterbusch, et al. Drug-free platelets can act as seeds for aggregate formation during antiplatelet therapy. Arterioscler Thromb Vasc Biol. 2015;35:2122–2133.
69. J.P.Bae, P.P.Dobesh, D.G.Klepser, et al. Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care. 2012;18:139–146.
70. J.Patrick, L.Dillaha, D.Armas, et al. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation. Postgrad Med. 2015;127:573–580.● Ref describes PK/PD of extended release ASA formulation Durlaza.
71. P.A.Gurbel, K.P.Bliden, J.Patrick, et al. Abstract 19503: Durability of antiplatelet effect of a novel extended-release formulation of acetylsalicylic acid, Durlaza in patients with diabetes. Circulation. 2015;132:A19503.
72. K.R.McQuaid, L.Laine. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119:624–638.
73. N.Brown, J.A.May, R.G.Wilcox, et al. Comparison of antiplatelet activity of microencapsulated aspirin 162.5 mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis. Br J Clin Pharmacol. 1999;48:57–62.
74. M.T.Donnelly, W.A.Stack, P.Richardson, et al. Microencapsulated aspirin, Asacard, reduces endoscopic damage in healthy volunteers compared to conventional encapsulated aspirin [abstract G0440]. Gastroenterology. 1998;114:A107.
75. R.C.Becker, J.P.Bassand, A.Budaj, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011;32:2933–2944.
76. P.A.Gurbel, A.Kuliopulos, U.S.Tantry. G-protein-coupled receptors signaling pathways in new antiplatelet drug development. Arterioscler Thromb Vasc Biol. 2015;35:500–512.
77. P.Vranckx, M.Valgimigli, S.Windecker, et al. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. EuroIntervention. 2015;7:11.
78. C.M.Gibson, R.Mehran, C.Bode, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015;169:472–478.